Company news
Oncology Pharma Inc. news in 2021
Oncology Pharma Inc.'s news releases, calls and decks from 2021, newest first.
Oncology Pharma Meeting Towards Future Developments
December 16, 2021
Oncology Pharma Year End Review and Outlook
December 8, 2021
Oncology Pharma Research and Vision
November 29, 2021
Oncology Pharma Reveals Plans for Development of Lead Cancer Drug Candidate
November 7, 2021
Oncology Pharma, Inc. Gives Update on Ongoing Work and Progress
October 26, 2021
Oncology Pharma, Inc. Has Engaged a PCAOB Audit Firm Looking Towards Moving the Company Towards a Senior Listing
October 14, 2021
Oncology Pharma, Inc. Update on PCAOB Audit Selection Process and License Agreement
October 11, 2021
Oncology Pharma, Inc. Has Received the Committed Funding to Perform All Necessary IND-Enabling Preclinical Work for Its First Lead Candidate, a Dactinomycin Nanoemulsion Drug Product
September 12, 2021
Oncology Pharma's Co-Development Agreement Pursues Strategic and Direct Objectives
August 22, 2021
Oncology Pharma, Inc. Executes Co-Development Agreement with NanoSmart Pharmaceuticals, Inc.
August 18, 2021
Oncology Pharma, Inc. To Move to Conducting Trials on Licensed IP
July 19, 2021
Oncology Pharma, Inc. is Entering Into the Next Phase of its Growth and Expansion Phase
June 29, 2021
Oncology Pharma, Inc. Eyes Collaboration with Patent Opportunities Amongst Its Licensed Intellectual Properties
June 14, 2021
Oncology Pharma and Ribera Solutions Release White Paper Regarding Patient Engagement and Retention Platform
June 8, 2021
Oncology Pharma, Inc. Is Pursuing the Development of Its Small Molecule Drug for the Treatment of Colon Cancer
May 17, 2021
Oncology Pharma, Inc. Has Submitted Its Initial Application to List the Company on the Capital Markets Tier of the NASDAQ Exchange
May 11, 2021
Oncology Pharma Enters into License Agreement for Small Molecules Intellectual Property for the Treatment of Colon Cancer
May 6, 2021
Oncology Pharma, Inc. Prepares Plan Toward Funding Development and Implementation of Ribera Solutions' Patient Engagement and Retention Platform
April 20, 2021
Oncology Pharma, Inc. Addresses Pancreatic Cancer, the Need for an Effective Therapy and the Potential of mRNA Technology
April 13, 2021
Oncology Pharma Signs License Agreement for mRNA Intellectual Property As It Reveals Strategic Plans for Treating Pancreatic Cancer
April 6, 2021
Oncology Pharma Has Provided Initial Funding to NanoSmart Pharmaceuticals to Conduct Feasibility Studies for Initial Phases of IND-Enabling Activities
March 31, 2021
Oncology Pharma Reveals Strategic Plans for Company Growth and Focus
March 16, 2021
Oncology Pharma, Inc. Vetting CROs to Develop Research Plan and Indications for Recently Licensed Cancer Combination Therapy
March 10, 2021
Oncology Pharma Moves to Fund Lead Drug Formulation & IND-Enabling Studies
March 4, 2021
Oncology Pharma Signs Worldwide Licensing Agreement with Sybleu, Inc. for Commercialization of Chemotherapeutic Agent in Combination with a Bioactive Immunostimulatory Agent
February 26, 2021
Oncology Pharma Extends Licensing Agreement with NanoSmart Pharmaceuticals, Inc. for Veterinary Oncology
February 22, 2021
Oncology Pharma is Pleased to Welcome New Chairman to Its Scientific Advisory Board
February 16, 2021
Oncology Pharma Renews Licensing Agreement With Ribera Solutions LLC for Its Connect2Med Clinical Trials Platform
February 9, 2021
Oncology Pharma Extends Its Licensing Agreement with NanoSmart Pharmaceuticals, Inc. for Human Oncology
February 3, 2021
Oncology Pharma Announces the Appointment Of New Chief Financial Officer
January 28, 2021